ApniCure is a technology company.
ApniCure has raised $5.0M across 1 funding round.
ApniCure has raised $5.0M in total across 1 funding round.
ApniCure has raised $5.0M in total across 1 funding round.
ApniCure's investors include U.S. Venture Partners.
# ApniCure: Medical Device Company Overview
ApniCure is a medical device company, not a technology company in the traditional sense. Founded in December 2007, the company is based in Redwood City, California, and specializes in developing home-use medical devices for treating obstructive sleep apnea (OSA) and related sleep disorders.[1][3] The company's flagship product is the Winx® Sleep Therapy System, which received FDA 510(k) clearance for home-use treatment of OSA.[1] ApniCure operates at the intersection of medical innovation and patient care, addressing a significant clinical challenge by offering an alternative therapeutic approach to conventional sleep apnea treatments.
The company employs 11-50 people and operates within the medical devices and equipment manufacturing sector.[1][6] Rather than building software or digital platforms, ApniCure focuses on commercializing proprietary hardware incorporating its Oral Pressure Therapy (OPT) platform technology—a novel mechanism designed specifically for sleep apnea management.[1]
ApniCure operates within the growing market for sleep disorder treatments, where OSA affects millions of patients globally. The company addresses a critical gap: many patients struggle with compliance and comfort using traditional continuous positive airway pressure (CPAP) devices. By developing a home-use alternative with a novel mechanism of action, ApniCure taps into demand for more patient-friendly therapeutic options. The timing aligns with broader healthcare trends emphasizing home-based care, personalized medicine, and improved patient adherence through better device design and comfort.
ApniCure represents a focused medical device innovator addressing a substantial clinical need with proprietary technology. The company's success depends on continued commercialization of the Winx system, clinical evidence supporting its efficacy and safety, and market adoption among sleep medicine practitioners and patients. As the company executes its product pipeline strategy, its influence will likely grow within the sleep medicine community, potentially establishing OPT as a recognized therapeutic category alongside existing OSA treatments.
ApniCure has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Venture Round in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $5.0M Venture Round | U.S. Venture Partners |